NK/T Cell Lymphoma: Updates in Therapy

@article{Suzuki2018NKTCL,
  title={NK/T Cell Lymphoma: Updates in Therapy},
  author={Ritsuro Suzuki},
  journal={Current Hematologic Malignancy Reports},
  year={2018},
  volume={13},
  pages={7-12}
}
  • R. Suzuki
  • Published 1 February 2018
  • Medicine, Biology
  • Current Hematologic Malignancy Reports
Purpose of ReviewExtranodal NK/T cell lymphoma (ENKL), nasal type, is a highly aggressive lymphoma which used to show a poor clinical outcome. Expression of P-glycoprotein on lymphoma cells of ENKL is a major reason for the refractoriness to conventional chemotherapy containing anthracycline. However, recent innovative approaches have improved the outcome and prognosis of ENKL. The purpose of this review is to summarize the proceedings of treatment.Recent FindingsConcurrent chemoradiotherapy… 
Progress in the treatment of NK-cell lymphoma/leukemia
TLDR
This review focuses on recent treatment approaches for NK/T cell lymphomas including novel agents and finds that allogeneic stem cell transplantation is the only curative treatment, and this is even applicable to chemo-resistant ANKL patients.
Extranodal NK/T-cell lymphoma: Updates in biology and management strategies.
Extranodal NK-/T-Cell Lymphomas and EBV+ Lymphoproliferative Diseases of Childhood
TLDR
Extranodal NK-/T-cell lymphoma (ENKTL) cells express multidrug resistance-associated P-glycoprotein, which actively export various cytotoxic agents outside the lymphoma cells, and CHOP or other anthracycline-based chemotherapy is usually ineffective.
Extranodal NK/T cell lymphoma, nasal type: an updated overview.
DDGP vs. SMILE in Relapsed/Refractory Extranodal Natural Killer/T‐cell Lymphoma, Nasal Type: A Retrospective Study of 54 Patients
TLDR
It is suggested that compared with SMILE chemotherapy, DDGP chemotherapy can significantly improve the response and survival of relapsed/refractory ENKL with better tolerance.
Study of L-Asparaginase, Vincristine, and Dexamethasone Combined With Intensity-modulated Radiation Therapy in Early-Stage Nasal NK/T-Cell Lymphoma
TLDR
In patients with early-stage nasal NKTCL, the LVD-IMRT regimen produced excellent, durable therapeutic benefit in most patients, with acceptable toxicity and no acute mortality.
Clinical efficacy of cisplatin, dexamethasone, gemcitabine and pegaspargase (DDGP) in the initial treatment of advanced stage (stage III–IV) extranodal NK/T-cell lymphoma, and its correlation with Epstein-Barr virus
TLDR
The DDGP regimen can significantly improve the clinical prognosis of NK/T-cell lymphoma patients with tolerable adverse reactions and the variation in EBV-DNA is correlated with clinical efficacy and prognosis, which provides a theoretical basis for NK/ T- cell lymphoma therapy.
Chemorefractory extranodal nasal-type natural-killer/T-cell lymphoma with great response to pembrolizumab in a young patient: a case report
TLDR
This case of chemorefractory extranodal natural-killer/T-cell lymphoma, nasal type, responded well to the novel drug pembrolizumab, which was able to control the disease.
HKDC1 C-terminal based peptides inhibit extranodal natural killer/T-cell lymphoma by modulation of mitochondrial function and EBV suppression
TLDR
It is concluded that HKDC1 C-terminal-based peptides inhibit ENKTL by modulation of mitochondrial function and EBV suppression.
Aberrant Expression of Prohibitin Is Related to Prognosis of Nasal Extranodal Natural Killer/T Cell Lymphoma, Nasal Type
TLDR
PHB may be a potential diagnostic marker and prognostic predictor of nasal ENKTCL, a high-grade Epstein-Barr virus-associated malignancy with poor outcomes.
...
...

References

SHOWING 1-10 OF 53 REFERENCES
PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK/T-cell lymphoma failing l-asparaginase.
TLDR
PD1 blockade with pembrolizumab was a potent strategy for NK/T-cell lymphomas failing l-asparaginase regimens and five CR patients were still in remission, the only adverse event was grade 2 skin graft-versus-host disease in one patient with previous allogeneic HSCT.
L-Asparaginase Induced Durable Remission of Relapsed Nasal NK/T-Cell Lymphoma After Autologous Peripheral Blood Stem Cell Transplantation
TLDR
A 60-year-old Japanese woman who presented with right nasal congestion and high fever was admitted to the authors' hospital in March 1999 and has been in second complete remission for more than 18 months since the completion of L-Asp treatment (as of July 2001).
L-Asparaginase-Based Induction Therapy for Advanced Extranodal NK/T-Cell Lymphoma
TLDR
Treatment of a patient with advanced extranodal NK/T-cell lymphoma, nasal type, with multiple subcutaneous lesions and hemophagocytic syndrome with an L-asparaginase-based induction therapy, which resulted in complete remission lasting longer than 2 years without additional treatment.
Successful Treatment with Erwinia l -Asparaginase for Recurrent Natural Killer/T Cell Lymphoma
TLDR
A patient with natural killer (NK)/T cell lymphoma who relapsed after autologous peripheral blood stem cell transplantation and was successfully treated with Escherichia coli and Erwinia l -asparaginase is described, resulting in regression of tumor and fever lysis.
Efficacy of L-asparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK/T-cell lymphoma, a phase 2 study.
TLDR
The results of a French prospective phase II trial of an L-asparaginase-containing regimen in 19 patients with relapsed or refractory disease treated in 13 centers confirm the excellent activity of L-Asparaginases-containing regimens in extranodal NK/T-cell lymphoma.
Cutaneous extranodal NK/T-cell lymphoma: a clinicopathologic study of 5 patients with array-based comparative genomic hybridization.
TLDR
ENK/T lymphoma is a very aggressive entity, and, in the authors' cases, the exclusively cutaneous presentation was not associated with a better prognosis, and the results of the array comparative genomic hybridization analysis could be useful to better define the different ENK/t lymphoma subgroups with cutaneous involvement.
Extranodal natural killer/T-cell lymphoma from skin or soft tissue: suggestion of treatment from multinational retrospective analysis.
  • H. Ahn, C. Suh, W. Kim
  • Medicine
    Annals of oncology : official journal of the European Society for Medical Oncology
  • 2012
TLDR
The prognostic value of KPI is identified and a treatment recommendation according to the TNM (tumour-node-metastasis) stage is suggested, and Radiotherapy with/without chemotherapy seemed to be optimal in localized disease.
Clinical efficacy of cisplatin, dexamethasone, gemcitabine and pegaspargase (DDGP) in the initial treatment of advanced stage (stage III–IV) extranodal NK/T-cell lymphoma, and its correlation with Epstein-Barr virus
TLDR
The DDGP regimen can significantly improve the clinical prognosis of NK/T-cell lymphoma patients with tolerable adverse reactions and the variation in EBV-DNA is correlated with clinical efficacy and prognosis, which provides a theoretical basis for NK/ T- cell lymphoma therapy.
PD1 blockade with low-dose nivolumab in NK/T cell lymphoma failing l-asparaginase: efficacy and safety
TLDR
Since employing PD1 blockade as an option for NK/T cell lymphomas failing L-asparaginase, three patients with informed consent treated three patients who could only afford another anti-PD1 antibody nivolumab, which if given at 40 mg (the smallest vial available) every 2 weeks (Q2W) was much cheaper than pembrolizumab.
Concurrent chemoradiotherapy followed by l-asparaginase-containing chemotherapy, VIDL, for localized nasal extranodal NK/T cell lymphoma: CISL08-01 phase II study
TLDR
CCRT followed by l-asparaginase-containing chemotherapy is a feasible treatment for newly diagnosed stages IE/IIE nasal ENKTL and grade III or IV hematologic toxicity was frequent during VIDL chemotherapy, no treatment-related mortality was observed, and l- asparaginases-associated toxicity was manageable.
...
...